Randox extends Grand National Festival Sponsorship for a further five years

Home - Archives for December 2020

Randox extends Grand National Festival Sponsorship for a further five years

Randox extends Grand National Festival Sponsorship for a further five years

22 December 2020: Randox extends Grand National Festival Sponsorship for a further five years

Randox has reached agreement with The Jockey Club for a five-year extension to its sponsorship of the world’s greatest steeplechase, the Grand National, and the three-day Grand National Festival staged at Aintree Racecourse.

The new agreement will run from 2022-2026, following on from the existing five-year deal which runs until next year. This ten-year sponsorship will be the second-longest partnership in the history of the Grand National.

As well as retaining headline naming rights for the three-day Grand National Festival, Randox will continue to sponsor all three races over the iconic Grand National fences; the Randox Foxhunters Chase on Liverpool’s NHS Day, the Randox Topham Chase on Ladies Day, and the iconic Randox Grand National on Grand National Day itself.

As the largest healthcare diagnostics company from the UK and Ireland, Randox undertakes research, development, manufacture and distribution of innovative laboratory tests and analysers. In 2019 Randox manufactured more than 4 billion tests and was active in 145 countries. The company employs more than 2,000 staff, including more than 450 research scientists and engineers, with key facilities located in Co Antrim and Co Donegal.

Randox focuses on the provision of comprehensive, accurate and timely testing in order to identify risk to health, improve clinical diagnoses and promote preventative healthcare; aiming to achieve better healthcare outcomes whilst reducing the burden on clinical services.

In early 2020 Randox recognised the threat from COVID-19 and, based on almost 40 years of diagnostic experience, quickly developed a test to accurately identify the virus. Testing at scale commenced within weeks to support both the UK’s National Testing Programme and private clients.

In March 2020, the company was processing 150 COVID-19 tests a day, but through investment and the enormous effort of its staff, Randox has been able to boost its laboratory testing capacity to process 90,000 COVID-19 samples per day for the UK Government’s National COVID-19 Testing Programme, making it the most productive laboratory in the UK and Ireland, and amongst the largest in Europe. It anticipates this climbing to 100,000 daily tests.

 Dr. Peter FitzGerald CBE, Founder and Managing Director of Randox, said:

“We have thoroughly enjoyed working with The Jockey Club’s team at Aintree and look forward to another successful five years, when we are once again able to come together to celebrate the Randox Grand National.”

“This terrible pandemic has increased understanding of the importance of diagnostics and testing across our society. As a company founded with the ultimate aim of saving lives, we will work hard to convert that better understanding into the improvement of people’s health in the future.”

Noting how the Grand National will now be known as the Randox Grand National from 2021 with ‘Health’ being removed from the name, Dr. FitzGerald, adds: 

“2020 has been a year of massive change and Randox has been at the forefront of countering the greatest pandemic to sweep these islands in 100 years. As a result, we are comfortable that our core company name is now synonymous with ‘health’ so are very happy to combine with Aintree to rebrand the world’s greatest steeplechase as, more succinctly, ‘the Randox Grand National’.

“We are excited for this new era of our partnership, of horse racing, and of society – in which COVID has taught us to appreciate the important things in life – our friends, our family, and our health. We very much look forward to the next five years.”

With around 9.5 million people tuning in each year in the UK through broadcast partners ITV, The Randox Grand National attracts one of the largest live TV audiences in sport. In 2017, ITV won a BAFTA for their exceptional coverage of the world’s greatest steeplechase. Worldwide the event attracts an estimated television audience of around 600 million.

Randox also continues as the Official Healthcare Partner of The Jockey Club. Founded in 1750 and today British Racing’s largest commercial group, The Jockey Club runs many of the sport’s most iconic assets which, as well as The Randox Grand National Festival, include the The Festival™ at Cheltenham, The Derby Festival at Epsom Downs and the National Stud, with all profits going back into the sport thanks to being a company incorporated by Royal Charter.

Dickon White, North West Regional Director for Jockey Club Racecourses, who runs Aintree, said:

“I am delighted that Randox has agreed to extend their sponsorship for the Grand National Festival for a further five years. It’s been a fantastic partnership over the past few years and we’ve been extremely impressed with their operation as well as their dedication to one of sports’ most iconic events.

“At a time when we are facing massive challenges in British racing, it is a tremendous boost to The Jockey Club, and a huge endorsement to the Grand National itself, that a new multi-year deal has been agreed with Randox.”

“The Randox Grand National continues to go from strength to strength and we look forward to working closely with Dr FitzGerald and his talented and committed team in the coming years.”

For further information please contact: Amy Millar – PR Team Leader on Amy.Millar@randox.com

Want to know more about Randox?

Contact us or visit our homepage to view more.

Our COVID-19 Products and Services

HOME TEST

ANTIBODY TEST

TRAVEL CERTIFICATE

LABORATORY TOOLS


Randox unveils SARS-CoV-2 antibody test to determine previous COVID-19 infection in just 1.5 hours

   

21st December 2020

Randox unveils SARS-CoV-2 antibody test to determine previous COVID-19 infection in just 1.5 hours

Randox Laboratories is proud to announce the launch of its new SARS-CoV-2 IgG test, utilising patented Randox Biochip Technology to simultaneously detect IgG antibodies that are reactive to both of the leading COVID-19 diagnostic antigens – Spike Receptor Binding Domain (RBD) and Nucleocapsid protein (NP).

Maximum test sensitivity is ensured through simultaneous detection of both RBD-only and NP-only responders, making it superior to current commercially available COVID-19 IgG tests that are based on RBD or NP alone, from which false negative results can occur.

The Randox SARS-CoV-2 IgG (RBD & NP) Array provides clinicians with an opportunity to discriminate vaccinated individuals from those naturally infected by COVID-19.

Lynsey Adams, Randox Clinical Marketing Manager commented;

“When there is little or no access to molecular testing, serology tests provide a means to quickly triage suspected cases of COVID-19, enabling appropriate case management, and guiding public health measures, such as quarantine or self-isolation.

 “The new Randox SARS-CoV-2 IgG (RBD & NP) Array, provides a unique insight into disease severity, is an established method of indirect disease diagnosis, and facilitates epidemiological surveillance as the COVID-19 pandemic progresses.”

 The Randox SARS-CoV-2 IgG (RBD & NP) Array has been developed for the Evidence Investigator, a semi-automated benchtop immunoassay analyser delivering accurate results in just 1.5 hours.

Features of the new Randox SARS-CoV-2 IgG (RBD & NP) Array

  • Utilises established diagnostic antigen candidates – RBD and NP
  • IgG measurement confirms adaptive immune response to SARS-CoV-2
  • Clinical specificity of 99.5%
  • Clinical sensitivity of 100% ≥ 14 days post SARS-CoV-2 PCR confirmation
  • Dual sample matrix: human serum/plasma.

Contact marketing@randox.com for further information on our latest SARS-CoV-2 array or click to find out more!

Randox in the media

Latest News

FAQs


Randox approved for COVID-19 test to release scheme

RANDOX approved for COVID-19 test to release

21 December 2020: RANDOX approved for COVID-19 test to release

Randox has been added to the Department of Health and Social Care’s list of private providers of coronavirus testing.

This includes the lists for both general testing and test to release, a scheme which is applicable to those in England who need to self-isolate on their return from international travel.

If after 5 days you take a test and receive a negative result, you can stop self-isolating.

To purchase your COVID-19 test kit for test to release, visit; https://www.randoxhealth.com/covid-19-home-testing-kit-2/

Please Note: The earliest you can take the test is 5 full days after you left the country not on the travel corridor list. Individuals who do not opt into the Test to Release scheme will need to self-isolate until 10 full days have passed since they were last in a country not on the travel corridors list.

To opt into the scheme, visit https://www.gov.uk/provide-journey-contact-details-before-travel-uk

You must complete this form within 48 hours of arriving back in the UK and will require your booking reference number and name of the test provider.

To view the list of test and release testing providers, visit; https://www.gov.uk/government/publications/list-of-private-providers-of-coronavirus-testing/list-of-private-providers-of-coronavirus-testing

It is important to keep up to date with government guidelines by visiting https://www.gov.uk/guidance/travel-advice-novel-coronavirus to find out more.

For further information please contact covidcustomersupport@randox.com

Want to know more about Randox?

Contact us or visit our homepage to view more.

Our COVID-19 Products and Services

HOME TEST

ANTIBODY TEST

TRAVEL CERTIFICATE

LABORATORY TOOLS


20th December 2020: 7 million tests on the National Testing Programme

Randox Logo

   

20TH DECEMBER: THE 7 MILLION MILESTONE 

We are pleased to let you know that on Sunday 20th December, Randox surpassed 7 million tests within the UK COVID-19 National Testing Programme.

That’s an incredible 7 million samples accessioned, tested and reported by our dedicated and talented staff.

Our staff are our best asset and have risen to the challenge this pandemic has created.

They have worked hard and flexibly, been creative and innovative, and pulled together as a team to make an impact in the fight against COVID-19.

We are very proud of their efforts and teamwork.

Let us once again say thank you to each and every member of Team Randox, for the efforts they have made in 2020.

What we do at Randox remains vital to the national and global management of COVID-19 and our work is making a real and positive difference.

We continue to work hard and improve, for the sake of our family, friends and communities.

For further information please email randoxpr@randox.com

Randox in the media

Latest News

FAQs


Vivalytic’s rapid coronavirus test delivers results for positive samples in less than 30 minutes

   

18th December 2020

Cloud-based software update means a faster PCR test for SARS-CoV-2

We are happy to announce that due to improved software for the Vivalytic analysis device, the CE marked Vivalytic SARS-CoV-2 rapid coronavirus test, which uses polymerase chain reactions (PCR), now delivers its results even faster. By applying optimized evaluation strategies, the Vivalytic analysis device can detect a positive SARS-CoV-2 sample through its high viral load in less than 30 minutes, right where the sample is collected.

This modified product is part of a research and development project relating specifically to COVID-19, funded by the German Federal Ministry of Education and Research (BMBF) to the tune of 4.97 million euros. The project’s aim is to expand the options for detecting acute infections of the coronavirus, looking particularly at on-the-spot testing in which the sample is analyzed in a fully automatic PCR process, as this offers rapid yet reliable results.

  • Improved software for Vivalytic: turnaround time for positive SARS-CoV-2 samples reduced to under 30 minutes.
  • Update from the cloud: Vivalytic analysis devices are updated over the internet.

Dr. Volkmar Denner, chairman of the board of management of Robert Bosch GmbH said;

“In the fight to contain the coronavirus pandemic, speed is of the essence. With Vivalytic, we are delivering cutting-edge medical technology. Our IT and software expertise have helped to make the Bosch Corona test for positive samples even faster – all within a short period of time.”

The new update is available for the SARS-CoV-2 singleplex test and the SARS-CoV-2 pooled test. Updating the Vivalytic testing devices is simple and straightforward – all that is required is an internet connection to access the Bosch cloud platform Vivasuite. Developed in-house at Bosch, the Vivasuite cloud platform allows users to digitally manage and update all their Bosch Healthcare Solutions devices. This is also an advantage when Vivalytic devices are in use in the field. The platform meets the strictest security standards and data privacy is guaranteed at all times: for example, there is no remote access to Vivalytic devices, and no possibility of accessing patient data.

The turnaround time for samples negative for SARS-CoV-2 is still 39 minutes. PCR tests are considered the gold standard, and Bosch’s rapid coronavirus tests have a sensitivity of 98 percent and a specificity of 100 percent.

Contact marketing@randox.com for further information on the latest vivalytic software update for SARS-CoV-2 testing. 

Randox in the media

Latest News

FAQs


Randox launches Mobile COVID-19 Lab for Workplace Testing

Randox launches Mobile COVID-19 Lab for Workplace Testing

11 December 2020: Randox launches Mobile COVID-19 Lab for Workplace Testing

World-leading diagnostics company Randox Laboratories has today unveiled a new Mobile Laboratory Service which will offer rapid and reliable COVID-19 workplace testing.

The service from Randox, which is the largest COVID-19 testing provider in the UK and Ireland, and a partner in the UK Government’s National COVID-19 Testing Programme, uses gold standard PCR technology to generate results in 1 – 3 hours.

Each Mobile Laboratory will be capable of processing up to 1000 samples per day, to allow employers to uphold COVID safety within the workplace and maintain maximum output.

Dr Peter FitzGerald, Randox Managing Director, said;

“As the nation continues to navigate the working challenges caused by the COVID-19 pandemic, an increasing number of organisations will want to implement a COVID-19 testing regime so that they can sustain safe working environments.

 “With this in mind we continue to expand our portfolio of bespoke testing products and services, and our latest addition, the Mobile Testing Laboratory, in conjunction with our work within the National Testing Programme, brings us one step closer to a timely return to a more normal society.”

As part of the Randox Mobile COVID-19 testing service, a team of healthcare professionals will collect the samples on site, and a Laboratory Technician will subsequently expedite the sample and reports the results.

The Mobile Laboratory is available across the UK from 14th December 2020.

Dr FitzGerald continued;

“Since a new study by researchers at the University College London revealed that 86% of people who tested positive for COVID-19 did not have virus symptoms1, frequent screening of asymptomatic patients, is vital to identify any hotspots and limit further spread.

 “Our Mobile COVID-19 Laboratory, which uses gold standard PCR technology and can visit the location of your choice for immediate service, will promote safe working practices, allow companies to demonstrate their commitment to their staff, and facilitate recovery of the UK economy.”

The Randox Mobile COVID-19 Laboratory comes fully staffed and stocked for testing, and is suitable for any and all industries – Construction, Aviation, Hospitality, Retail and more.

Find out more at https://www.randoxhealth.com/mobile-covid-19-testing-laboratory/

For further information please email mobiletesting@randox.com

 

References

    1 https://www.ucl.ac.uk/news/2020/oct/symptoms-covid-19-are-poor-marker-infection  

    Want to know more about Randox?

    Contact us or visit our homepage to view more.

    Our COVID-19 Products and Services

    HOME TEST

    ANTIBODY TEST

    TRAVEL CERTIFICATE

    LABORATORY TOOLS


    Randox plans to build new Covid-19 testing lab at Donegal site

    Randox Logo

       

    04 December: Randox Laboratories plans to build new Covid-19 testing lab at Donegal site

    Healthcare diagnostics company Randox has announced it plans to build a new Covid-19 testing laboratory at Randox Teoranta in Dungloe.

    The company, a partner in the UK’s National Covid-19 Testing Programme, is expected to open the new lab in Donegal in early 2021.

    The facilities will complement the already existing Covid labs at its County Antrim site, which has completed more than six million tests since the coronavirus pandemic began.

    Randox Founder and Managing Director Dr Peter FitzGerald, commented;

    “Our research and development facility at Randox Teoranta in Dungloe is already responsible for about 14% of our overall manufacturing and R&D work, and a lot of the technology we have developed there is fundamental to our work – not only for Covid-19 but for other health issues including Alzheimer’s disease, Chronic Kidney Disease and Stroke.

    “Our new Covid-19 laboratory in Donegal is an exciting new capability which will, when complete, add significant capacity to Randox’s current Covid-19 testing programme.”

    With its overall daily testing capacity having grown from just 150 tests a day in March this year, to 80,000 tests in December, Randox has taken on more than 750 new staff this year.

    The company, which now conducts testing for passengers at Dublin Airport, hopes to create up to 50 new jobs at Randox Teoranta in support of the new Covid-19 laboratory.

    Dr FitzGerald continued;

    “We are very lucky at Randox that we benefit from a strong talent pool of candidates across science, engineering and manufacturing, and those with experience in these areas have responded well to our call for support in the fight against Covid-19.

    “We look forward to expanding our team at Randox Teoranta so that we may continue to retain and attract top scientific talent within Ireland.”

    Randox Teoranta, based in Dungloe, County Donegal, was established in 2008, is a client company of Údarás na Gaeltachta, and currently employs 110 people.

    For further information please email randoxpr@randox.com

    Randox in the media

    Latest News

    FAQs


    The Six Million Tests Milestone: 2nd December 2020

    Randox Logo

       

    2ND DECEMBER: THE 6 MILLION MILESTONE 

    We are pleased to let you know that on 2nd December, Randox surpassed 6 million tests within the UK COVID-19 National Testing Programme.

    That’s an incredible 6 million samples accessioned, processed and tested by our dedicated and talented staff.

    Our staff are our best asset and have risen to the challenge this pandemic has created.

    They have worked hard and flexibly, been creative and innovative, and pulled together as a team to make an impact in the fight against COVID-19.

    We are very proud of their efforts and teamwork.

    Let us once again say thank you to each and every member of Team Randox, for the efforts they have made in 2020.

    What we do at Randox remains vital to the national and global management of COVID-19 and our work is making a real and positive difference.

    We continue to work hard and improve, for the sake of our family, friends and communities.

    For further information please email randoxpr@randox.com

    Randox in the media

    Latest News

    FAQs


    Request a meeting
    ×
    Make an Enquiry - RX series
    ×
    Make an Enquiry - Reagents
    ×
    Kit Insert Request - Reagents
    • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
    ×
    Kit Insert Request - Reagents
    • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
    ×
    Make an Enquiry - Reagents
    ×
    Make an Enquiry - Quality Control
    ×
    Make an Enquiry - RIQAS
    ×
    Make an Enquiry - RIQAS
    ×
    Make an Enquiry - Quality Control
    ×
    Make an Enquiry
    • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
    ×
    Make an Enquiry - Biochip
    • This field is for validation purposes and should be left unchanged.
    ×
    Make an Enquiry - Molecular
    • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
    • This field is for validation purposes and should be left unchanged.
    ×
    Make an Enquiry - Future Diagnostics
    ×
    Make an Enquiry - RX series (Product)
    ×
    Make an Enquiry - Quality Control
    • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
    ×
    Make an Enquiry - RIQAS
    • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
    ×
    Make an Enquiry - Reagents
    • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
    ×
    Por favor, introduzca sus datos para ver nuestro último seminario
    ×
    Wyślij zapytanie
    • Rejestracja na naszej liście mailowej jest szybka i łatwa. Nie chcemy wysyłać e-maili zawierających spam lub wiadomości, które są automatycznie przekierowywane do kosza. W zawiązku z czym firma Randox deklaruje, że będzie wysyłac tylko informacje na temat nowych produktów,akutalizacji obecnych, trendów rynkowych, wydarzeń branżowych itp. Firma Randox Laboraotries obiecuje, że Państwa dane nie będą nigdzie przekazane, a przechowywanie owych danych będzie się odbywało z zachowaniem największego bezpieczeństwa. Prosimy o przeczytani naszje Polityki Prywatności.
    ×
    Wyślij zapytanie
    • Rejestracja na naszej liście mailowej jest szybka i łatwa. Nie chcemy wysyłać e-maili zawierających spam lub wiadomości, które są automatycznie przekierowywane do kosza. W zawiązku z czym firma Randox deklaruje, że będzie wysyłac tylko informacje na temat nowych produktów,akutalizacji obecnych, trendów rynkowych, wydarzeń branżowych itp. Firma Randox Laboraotries obiecuje, że Państwa dane nie będą nigdzie przekazane, a przechowywanie owych danych będzie się odbywało z zachowaniem największego bezpieczeństwa. Prosimy o przeczytani naszje polityki prywatności.
    ×
    Wyślij zapytanie
    • Rejestracja na naszej liście mailowej jest szybka i łatwa. Nie chcemy wysyłać e-maili zawierających spam lub wiadomości, które są automatycznie przekierowywane do kosza. W zawiązku z czym firma Randox deklaruje, że będzie wysyłac tylko informacje na temat nowych produktów,akutalizacji obecnych, trendów rynkowych, wydarzeń branżowych itp. Firma Randox Laboraotries obiecuje, że Państwa dane nie będą nigdzie przekazane, a przechowywanie owych danych będzie się odbywało z zachowaniem największego bezpieczeństwa. Prosimy o przeczytani naszje polityki prywatności.